NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...

Universal access to GLP-1 receptor agonists for eligible populations could reduce global obesity prevalence by half and save ...

Novo Nordisk A/S (NYSE:NVO) saw its stock decline 2.1% in premarket trading after Spain’s health ministry initiated an ...

Investing.com -- Novo Nordisk A/S (NYSE: NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which ...

US Health Secretary Kennedy says HHS to launch campaign to encourage wearable devices – Nation and World News | West Hawaii Today ...

Berger Montague, a nationally recognized securities litigation firm, is investigating potential claims on behalf of investors who purchased or otherwise acquired securities of Hims ...

A massive U.S. study found diabetics on semaglutide (Ozempic’s active ingredient) had up to 70% lower risk of ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...

In a statement on Monday, Amgen Inc. (NASDAQ:AMGN) announced that its phase 2 study of its weight loss drug candidate, ...

Amanda Bynes revealed that she plans to use the injectable drug Ozempic to help achieve her weight loss goals, noting she ...

A $10.2 million savings across more than 100,000 prescriptions over three months, extrapolated across the nearly 33 million Americans currently taking GLP-1 medications monthly, indicates a potential ...